Literature DB >> 23221166

The dependence of optimal fractionation schemes on the spatial dose distribution.

Jan Unkelbach1, David Craft, Ehsan Salari, Jagdish Ramakrishnan, Thomas Bortfeld.   

Abstract

We consider the fractionation problem in radiation therapy. Tumor sites in which the dose-limiting organ at risk (OAR) receives a substantially lower dose than the tumor, bear potential for hypofractionation even if the α/β-ratio of the tumor is larger than the α/β-ratio of the OAR. In this work, we analyze the interdependence of the optimal fractionation scheme and the spatial dose distribution in the OAR. In particular, we derive a criterion under which a hypofractionation regimen is indicated for both a parallel and a serial OAR. The approach is based on the concept of the biologically effective dose (BED). For a hypothetical homogeneously irradiated OAR, it has been shown that hypofractionation is suggested by the BED model if the α/β-ratio of the OAR is larger than α/β-ratio of the tumor times the sparing factor, i.e. the ratio of the dose received by the tumor and the OAR. In this work, we generalize this result to inhomogeneous dose distributions in the OAR. For a parallel OAR, we determine the optimal fractionation scheme by minimizing the integral BED in the OAR for a fixed BED in the tumor. For a serial structure, we minimize the maximum BED in the OAR. This leads to analytical expressions for an effective sparing factor for the OAR, which provides a criterion for hypofractionation. The implications of the model are discussed for lung tumor treatments. It is shown that the model supports hypofractionation for small tumors treated with rotation therapy, i.e. highly conformal techniques where a large volume of lung tissue is exposed to low but nonzero dose. For larger tumors, the model suggests hyperfractionation. We further discuss several non-intuitive interdependencies between optimal fractionation and the spatial dose distribution. For instance, lowering the dose in the lung via proton therapy does not necessarily provide a biological rationale for hypofractionation.

Entities:  

Mesh:

Year:  2012        PMID: 23221166     DOI: 10.1088/0031-9155/58/1/159

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  7 in total

Review 1.  Hyperfractionated and accelerated radiotherapy in non-small cell lung cancer.

Authors:  Kate Haslett; Christoph Pöttgen; Martin Stuschke; Corinne Faivre-Finn
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

2.  Simultaneous optimization of dose distributions and fractionation schemes in particle radiotherapy.

Authors:  Jan Unkelbach; Chuan Zeng; Martijn Engelsman
Journal:  Med Phys       Date:  2013-09       Impact factor: 4.071

3.  Optimization of radiation dosing schedules for proneural glioblastoma.

Authors:  H Badri; K Pitter; E C Holland; F Michor; K Leder
Journal:  J Math Biol       Date:  2015-06-21       Impact factor: 2.259

4.  Technical Note: Break-even dose level for hypofractionated treatment schedules.

Authors:  Till Tobias Böhlen; Jean-François Germond; Jean Bourhis; Marie-Catherine Vozenin; Claude Bailat; François Bochud; Raphaël Moeckli
Journal:  Med Phys       Date:  2021-10-22       Impact factor: 4.506

5.  Comparison of the average surviving fraction model with the integral biologically effective dose model for an optimal irradiation scheme.

Authors:  Ryo Takagi; Yuriko Komiya; Kenneth L Sutherland; Hiroki Shirato; Hiroyuki Date; Masahiro Mizuta
Journal:  J Radiat Res       Date:  2018-03-01       Impact factor: 2.724

Review 6.  Optimal treatment and stochastic modeling of heterogeneous tumors.

Authors:  Hamidreza Badri; Kevin Leder
Journal:  Biol Direct       Date:  2016-08-23       Impact factor: 4.540

7.  Comparing conformal, arc radiotherapy and helical tomotherapy in craniospinal irradiation planning.

Authors:  Pamela A Myers; Panayiotis Mavroidis; Nikos Papanikolaou; Sotirios Stathakis
Journal:  J Appl Clin Med Phys       Date:  2014-09-08       Impact factor: 2.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.